### **ORIGINAL ARTICLE**

# Relationship between hospital length of stay and quality of care in patients with congestive heart failure

M P Kossovsky, F P Sarasin, P Chopard, M Louis-Simonet, P Sigaud, T V Perneger, J-M Gaspoz

Qual Saf Health Care 2002;11:219-223

**Objective:** To determine the relationship between hospital length of stay (LOS) and quality of care in patients admitted for congestive heart failure (CHF).

**Methods:** This observational study was conducted in the medical wards of the Geneva University Hospitals, Geneva, Switzerland. A random sample of 371 patients was drawn from the 1084 patients discharged alive with a principal diagnosis of CHF between January 1997 and December 1998. Explicit criteria grouped into three scores were used to assess the quality of processes of care: admission work-up (admission score); evaluation and treatment during the stay (treatment score); and readiness for discharge (discharge score). The association between LOS and quality of care was analysed using linear regression with adjustment for clinical characteristics.

**Results:** The mean proportion of criteria met were 80% for the admission score, 66% for the treatment score, and 76% for the discharge score. Mean (SD) LOS was 13.2 (8.8) days. The admission score was not associated with LOS, but the treatment score increased by 0.5% (95% Cl 0.3 to 0.7; p<0.001) with each additional day in hospital and the discharge score increased by 2.5% (95% Cl 1.6 to 3.3; p<0.001) per day from admission to day 10 but remained unchanged thereafter. Adjustment for potential confounders did not substantially modify these relationships.

**Conclusions:** In patients with CHF there is a significant association between LOS and the quality of the treatment provided, as well as with readiness for discharge. Appropriate reorganisation of processes of care should accompany attempts at reducing LOS to avoid detrimental effects on quality of care.

• ongestive heart failure (CHF) is among the leading causes of hospitalisation in most developed ✓ countries.<sup>1-4</sup> Most of the costs of treating this disease are generated by hospital admissions, so reducing the length of stay (LOS) in hospital may yield significant savings.<sup>25</sup> However, understanding a patient's situation, performing investigations, and selecting the appropriate treatment requires time. Shortening the hospital LOS may therefore increase the risk of not completing the evaluations and treatments needed and of discharging insufficiently stabilised patients. On the other hand, once investigations and treatments have been completed, no additional benefit will accrue from extending the hospital stay. Keeping patients in hospital longer than necessary generates unnecessary costs and exposes patients to complications such as nosocomial infections. To understand better how quality of care relates to the duration of hospitalisation, we have examined the relationship between LOS and explicit quality of care criteria in patients with CHF.

#### METHODS Setting and patients

The study was conducted in the general internal medicine wards of the University Hospitals of Geneva, Switzerland. This 1200 bed urban public hospital is the main community and teaching hospital for the area. A random sample of 371 patients was drawn from the 1084 patients discharged alive with a principal diagnosis of CHF between 1 January 1997 and 31 December 1998. Patients were identified in the hospital medical database using ICD9-CM codes 398-91, 402-01, 402-11, 402-91, 404-01, 404-03, 404-11, 404-13, 404-91, 404-93, and 428.<sup>6</sup>

#### **Outcome variables**

The main outcome variable was the quality of in-hospital care measured by published explicit criteria developed by an expert panel from the Baylor College of Medicine, Houston, Texas in 1993.<sup>7</sup> The criteria were divided into three subgroups corresponding to successive hospitalisation phases: (1) admission work-up; (2) evaluation and treatment during the stay; and (3) readiness for discharge (box 1). The detailed list is available at the website http://www.medinter.ch/grassh.

As many criteria were not applicable to all patients, we calculated the proportion of fulfilled criteria in those applicable to each hospitalisation phase. We thus had three quality scores corresponding to each phase of the hospital stay: an admission score, a treatment score, and a discharge score. All information was abstracted from patients' charts by a trained nurse who was not blinded to LOS, but who was not aware of the fact that LOS was of particular interest in the analysis.

#### **Predictor variables**

The main predictor variable of quality of hospital care analysed was LOS. Other variables were potential confounders:

(1) sociodemographic data: age, sex, and whether the patient lived alone;

(2) medical data: diagnosis of CHF known before admission to hospital, hypertension, diabetes, history of acute myocardial infarction, history of cardiac revascularisation by percutaneous transluminal coronary angioplasty or coronary artery bypass grafting, and intubation during the index stay;

(3) physical and laboratory findings on admission: systolic blood pressure, heart rate, serum sodium level, plasma creatinine level, rhythm and/or ST-T wave changes on admission ECG, and left ventricular ejection fraction.

See end of article for authors' affiliations

Correspondence to: Dr M Kossovsky, Clinique de Médecine II, Département de Médecine Interne, Hôpitaux Universitaires de Genève, 1211 Geneva 14, Switzerland; michel.picard-kossovsky@ hcuge.ch

Accepted for publication 17 April 2002

#### I. Admission work-up criteria

- History taking about:
  - symptoms of CHF
  - past history of CHF
- Physical examination:
- vital signs
- neck vein distension
- . .
- Laboratory tests on admission:
  - blood count
  - serum electrolytes
  - •

## II. Criteria for evaluation and treatment during the stay

- Specific diagnostic tests:
- diagnostic thoracocentesis, when appropriate
- echocardiogram, when appropriate
- . . .
- Treatment strategies:
  - oxygen supply, when appropriate
  - low dose heparin subcutaneously, when appropriate
  - vasodilator therapy
  - . . .

#### III. Readiness for discharge criteria

Significant improvement in symptoms and signs

- Body weight stable or decreasing
- No change in cardiac medication for at least 24 hours
  ...

Adapted and summarised from Ashton *et al.*<sup>7</sup> A complete list of the criteria with conditions of applicability and skip patterns are available at http://www.medinter.ch/grassh

Mean (SD) age (years)       75.5         Mean (SD) heart rate on admission (beats/min)       93 (;         Mean (SD) systolic BP on admission (mm Hg)       147         Mean (SD) Charlson comorbidity index       2.7         Mean (SD) left ventricular ejection fraction (%)       34 (         (n=172)       194         Living alone, n (%)       194         Living alone, n (%)       156         History of revascularisation, n (%)       67 (         History of myocardial infarction, n (%)       204         Known hypertension, n (%)       204         Known diabetes mellitus, n (%)       86 (;         Hypotension on admission, n (%)       21 (;	(11.1) 29) (30) 2.1)
Mean (SD) heart rate on admission (beats/min)       93 (;         Mean (SD) systolic BP on admission (mm Hg)       147         Mean (SD) Charlson comorbidity index       2.7         Mean (SD) left ventricular ejection fraction (%)       34 (         (n=172)       194         Living alone, n (%)       194         Living alone, n (%)       156         History of revascularisation, n (%)       67 (         History of myocardial infarction, n (%)       204         Known diabetes mellitus, n (%)       86 (;         Hypotension on admission, n (%)       21 (;	29) (30) 2.1) 2)
Mean (SD) systolic BP on admission (mm Hg)       147         Mean (SD) Charlson comorbidity index       2.7         Mean (SD) left ventricular ejection fraction (%)       34 (         (n=172)       194         Living alone, n (%)       194         Living alone, n (%)       156         History of revascularisation, n (%)       67 (         History of myocardial infarction, n (%)       204         Known hypertension, n (%)       204         Hypotension on admission, n (%)       21 (	(30) 2.1) 2)
Mean (SD) Charlson comorbidity index       2.7         Mean (SD) left ventricular ejection fraction (%)       34 (         (n=172)       194         Living alone, n (%)       194         Living alone, n (%)       170         Known prior CHF, n (%)       156         History of revascularisation, n (%)       67 (         History of myocardial infarction, n (%)       204         Known hypertension, n (%)       204         Known diabetes mellitus, n (%)       86 (         Hypotension on admission, n (%)       21 (	2.1) 2)
Mean (SD) left ventricular ejection fraction (%)       34 (         (n=172)       194         Living alone, n (%)       170         Known prior CHF, n (%)       156         History of revascularisation, n (%)       67 (         History of myocardial infarction, n (%)       204         Known hypertension, n (%)       204         Known diabetes mellitus, n (%)       86 (         Hypotension on admission, n (%)       21 (	21
(n=172)         Men, n (%)         194           Living alone, n (%)         170           Known prior CHF, n (%)         156           History of revascularisation, n (%)         67 (           History of myocardial infarction, n (%)         126           Known hypertension, n (%)         204           Known diabetes mellitus, n (%)         86 (           Hypotension on admission, n (%)         21 (	
Men, n (%)         194           Living alone, n (%)         170           Known prior CHF, n (%)         156           History of revascularisation, n (%)         67 (           History of myocardial infarction, n (%)         126           Known hypertension, n (%)         204           Known diabetes mellitus, n (%)         86 (           Hypotension on admission, n (%)         21 (	,
Living alone, n (%)170Known prior CHF, n (%)156History of revascularisation, n (%)67 (History of myocardial infarction, n (%)126Known hypertension, n (%)204Known diabetes mellitus, n (%)86 (Hypotension on admission, n (%)21 (	(52.3%)
Known prior CHF, n (%)156History of revascularisation, n (%)67 (History of myocardial infarction, n (%)126Known hypertension, n (%)204Known diabetes mellitus, n (%)86 (Hypotension on admission, n (%)21 (	(47.5%)
History of revascularisation, n (%)     67 (       History of myocardial infarction, n (%)     126       Known hypertension, n (%)     204       Known diabetes mellitus, n (%)     86 (       Hypotension on admission, n (%)     21 (	(43.5%)
History of myocardial infarction, n (%)126Known hypertension, n (%)204Known diabetes mellitus, n (%)86 (Hypotension on admission, n (%)21 (	8.1%)
Known hypertension, n (%)204Known diabetes mellitus, n (%)86 (Hypotension on admission, n (%)21 (	(34.1%)
Known diabetes mellitus, n (%)86 (;Hypotension on admission, n (%)21 (;	(55.0%)
Hypotension on admission, n (%) 21 (	23.2%)
	5.7%)
Hyponatraemia on admission, n (%) 60 (	6.2%)
Creatinaemia >265.2 µmol/l on admission, n (%) 16 (	4.4%)
Non-sinus cardiac rhythm on admission, n (%) 131	105 100
New ST-T changes on admission, n (%) 179	(35.6%)
Admission to an ICU, n (%) 65 (	(35.6%) (52.7%)
Intubation during the stay, n (%) 13 (	(35.6%) (52.7%) 7.5%)

Comorbidities were assessed and scored according to Charlson *et al.*<sup>8</sup> This score assesses whether diseases which were not the cause of the hospitalisation were present at admission. They are rated according to their influence on mid term survival. Diseases that have a minor influence on survival (history of an old myocardial infarction, diabetes without complications, or chronic obstructive pulmonary disease) are scored 1 point; more severe disorders (renal failure, diabetes with complications, cancer, leukaemia or lymphoma in remission for less than 10 years) are scored 2 points; severe hepatic diseases such as cirrhosis with ascites or with upper gastrointestinal bleed-



Figure 1 Relationship between hospital length of stay and scores assessing quality of care: (A) admission score; (B) treatment score; (C) discharge score.

ing are scored 4 points; and short term life threatening disorders such as metastatic cancer or AIDS are scored 6 points.

#### **Statistical analysis**

The association between each quality score (admission, treatment and discharge) and LOS was examined using locally weighted smoothing scatterplots (LOWESS).<sup>9</sup> The influence of each additional hospital day on the different scores was tested in linear regression models. Variables reflecting patients' demographic and clinical characteristics that were significantly associated with quality of care in univariate analysis were incorporated into multivariate linear regression models. Two way interactions between LOS and potential confounding variables were also tested. Backward elimination was used until all remaining variables in the models reached a significance level of 0.05 or less.

#### RESULTS

The characteristics of the 371 patients included in the study are shown in table 1. None of the patients stayed in hospital for less than 24 hours; the mean (SD) LOS was 13.2 (8.8) days (median 11 days, range 2–77 days). The mean (SD) admission, treatment, and discharge scores were 79.6 (5.8)%, 66.1 (17.2)%, and 76.0 (19.5)%, respectively.

Graphical analysis of the associations between LOS and admission, treatment, and discharge scores (fig 1) showed that:

• the admission score was not associated with LOS (fig 1A) and was not analysed further;

**Table 2** Univariate association between independent variables and the proportion of quality of care criteria observed for evaluation and treatment during the stay (treatment score) and readiness for discharge (discharge score)

	Treatment score			Discharge score			
	Difference	95% CI	p value	Difference	95% CI	p value	
Length of stay (for each additional day)	0.48	0.3 to 0.7	< 0.001	2.46	1.6 to 3.3	<0.001	
Age (for each additional decade)	-4.08	–5.6 to –2.6	<0.001	2.07	0.3 to 3.8	0.02	
Men	2.96	–0.5 to 6.5	0.09	-4.26	-8.2 to -0.3	0.04	
Living alone	-0.66	-4.3 to 2.9	0.72	5.25	1.3 to 9.2	0.01	
Known prior CHF	1.85	-1.8 to 5.5	0.32	-1.28	-5.4 to 2.8	0.54	
History of revascularisation	5.30	0.8 to 9.88	0.02	-3.89	-9.1 to 1.3	0.14	
History of myocardial infarction	0.64	-3.1 to 4.4	0.73	-0.71	-4.9 to 3.5	0.74	
Known hypertension	0.64	-2.9 to 4.2	0.72	-0.95	-5.0 to 3.1	0.64	
Known diabetes mellitus	0.82	-3.3 to 5.0	0.70	0.55	-4.2 to 5.3	0.82	
Hypotension on admission	0.33	–7.3 to 7.9	0.93	-2.37	-11.0 to 6.2	0.59	
Hyponatraemia on admission	-3.18	–8.0 to 1.6	0.19	1.75	-3.7 to 7.2	0.53	
Serum creatinine >265.2 µmol/l on admission	2.24	-6.4 to 10.9	0.61	3.68	-6.2 to 13.5	0.46	
Non-sinus cardiac rhythm on admission	1.97	–1.7 to 5.6	0.29	-2.08	-6.3 to 2.1	0.33	
Heart rate on admission (for 10 bpm increase)	0.73	0.0 to 1.4	0.04	0.88	0.1 to 1.7	0.03	
Systolic BP on admission (for 10 mm Hg increase)	-0.18	–0.8 to 0.4	0.56	0.19	–0.5 to 0.9	0.58	
New ST–T changes on admission	1.57	–2.7 to 5.2	0.40	3.44	–0.8 to 7.6	0.11	
Admission to an ICU	8.82	4.3 to 13.4	<0.001	-0.38	-5.6 to 4.9	0.89	
Intubation during the stay	7.85	0.6 to 15.1	0.04	2.36	-6.0 to 10.7	0.58	
Charlson comorbidity index (for 1 point increase)	-0.15	-1.0 to 0.7	0.73	0.14	-0.8 to 1.1	0.76	
Ejection fraction (n=172) (for 10% improvement)	-1.62	-3.5 to 0.3	0.09	-0.19	-0.5 to 0.1	0.16	

 Table 3
 Multivariate association between independent variables and the proportion of quality of care criteria observed for evaluation and treatment during the stay (treatment score) and readiness for discharge (discharge score)

	Treatment score			Discharge score		
	Difference	95% CI	p value	Difference	95% CI	p value
Length of stay (for each additional day)	0.5	0.3 to 0.6	<0.001	-	-	_
Length of stay (for each additional day between days 1 and 10)	-	-	-	2.6	1.7 to 3.4	<0.001
Age (for each additional decade)	-3.8	-5.2 to -2.3	<0.001	1.8	0.1 to 3.6	0.04
Admission to an ICU	5.1	0.7 to 9.5	0.02	-	-	-
Living alone	-	-	-	4.0	0.2 to 7.9	<0.001

**Table 4**Association between each additional day of hospital length of stay (LOS)and the odds of fulfilling individual quality of care criteria significantly associatedwith LOS. Non-significant associations are not shown

Criteria assessing quality of evaluation and treatment during hospital stay	Eligible patients	Odds ratio (95% CI) per day of LOS	p value
Evaluation and treatment			
Diagnostic thoracocentesis	146	1.12 (1.05 to 1.19)	<0.001
Echocardiogram	310	1.05 (1.01 to 1.10)	0.007
24 h ECG	33	1.32 (1.05 to 1.64)	0.02
Daily weights obtained	368	1.07 (1.02 to 1.13)	0.007
Potassium supplement given	86	1.21 (1.04 to 1.41)	0.01
Low dose heparin or fulldose anticoagulation	347	1.10 (1.03 to 1.18)	0.004
Readiness for discharge			
Improvement in dyspnoea	370	1.13 (1.01 to 1.25)*	0.02
Improvement in neck vein distention	370	1.15 (1.04 to 1.27)*	0.007
Improvement in pulmonary auscultation	368	1.12 (1.01 to 1.24)*	0.03
Body weight stable or decreasing	359	1.14 (1.02 to 1.28)*	0.02
Temperature <38.5°C in last 24 h	371	1.14 (1.02 to 3.86)*	0.04
No change in cardiac medications in last 24 h	353	1.21 (1.10 to 1.34)*	< 0.001
INR reached a plateau	109	1.23 (1.00 to 1.51)*	0.05
Plans for post-discharge care stated on chart	371	1.17 (1.06 to 1.28)*	0.001

- the treatment score was linearly associated with LOS (fig 1B) and was further analysed in a simple linear model;
- the discharge score was associated with LOS during the first 10 days in hospital (fig 1C) so further analysis was focused on the initial phase of the hospitalisation.

Each additional day in hospital was associated with an increase in the treatment score of 0.5% (95% CI 0.3 to 0.7; p<0.001) and each day of LOS between days 2 and 10 was associated with an increase in the discharge score of 2.5% (95% CI 1.6 to 3.3; p<0.001).

Unadjusted analysis (table 2) showed that a higher treatment score had a significantly positive association with younger age, a history of myocardial revascularisation, a faster heart rate on admission, admission to an ICU during the hospital stay, and undergoing an intubation during the hospital stay; it had a significantly negative association with age. The discharge score was higher in women, older patients, those living at home alone, and in patients with a faster heart rate on admission.

In multivariate analysis (table 3) the treatment score remained positively associated with each additional day in hospital, admission to an ICU during the stay, and younger age, while each additional day between days 2 and 10, older age, and living at home alone were positively associated with a higher discharge score. However, none of these potential confounders substantially modified the relationship between LOS and either the treatment or the discharge scores.

Associations between each individual quality of care criteria and LOS varied from one criterion to the next. In unadjusted analysis (table 4) LOS was significantly associated with the following treatment criteria: performance of a diagnostic thoracocentesis; performance of an echocardiogram; performance of a 24 hour electrocardiogram; weight measurement obtained daily; restriction of activity; and use of low dose heparin. LOS between days 1 and 10 was significantly associated with the following discharge criteria: improvement in dyspnoea; improvement in pulmonary auscultation; improvement in neck vein distension; stable or decreased body weight; and no change in cardioactive medications during 24 hours before discharge. The other criteria showed no relationship with LOS.

#### DISCUSSION

At our institution each additional hospital day was significantly and independently associated with the proportion of fulfilled criteria assessing the quality of evaluation and treatment during the stay of patients with CHF. The same was true for criteria assessing the readiness for discharge up to day 10. In contrast, fulfilment of criteria assessing the completeness of the admission work-up was not related to LOS. The latter finding is not surprising since admission work-up takes place in the first 2 days of the hospital stay and is therefore logically independent of the subsequent duration of the hospital stay. The theoretical coherence of this negative finding lends credibility to the positive associations that we found between LOS and other aspects of quality of care.

In principle, tests and treatments can be organised effectively to allow a short LOS without compromising quality of care. However, the relationship that we observed between LOS and the fulfilment of criteria assessing the quality of care suggests that reducing LOS beyond a certain limit may jeopardise quality of care.

Because this was an observational study we do not know whether a deliberate reduction in LOS, especially if it is accompanied by an intervention to maintain standards of care, would have a similarly deleterious impact on quality of care. Several studies have shown no detrimental effects of shorter hospital stays on various patient outcomes such as hospital readmissions or death in the weeks following discharge.<sup>10-12</sup> This apparent contradiction may be explained by the fact that these outcomes were more closely related to patient characteristics than to in-hospital quality of care<sup>13</sup> <sup>14</sup> or that the quality of ambulatory care after the stay may have corrected substandard care during the hospital stay, especially if the patients were included in a formal post-hospitalisation programme.<sup>15</sup>

A relationship between long LOS and the occurrence of in-hospital complications has been reported.<sup>16–18</sup> In these studies, however, long LOS is often a consequence of a complication which, in turn, may be related to poor quality of

#### Key messages

- In patients admitted to hospital with congestive heart failure, a significant association was found between length of stay and the quality of treatment provided, as well as with readiness for discharge.
- Adequate care may require a sufficient length of stay.
- Reducing the length of stay may affect quality of care, unless processes of care are redesigned accordingly.

care. The causal link is therefore reversed. In the present study we did not have sufficient power to show an association between quality of care and poorer survival after discharge. However, we found a significant association between lower discharge score and increased unplanned early readmissions.<sup>14</sup>

The mean LOS of 13.2 days observed in our study exceeds that reported from the USA<sup>1 12</sup> but is similar to that of other countries such as Scotland,<sup>19</sup> the Netherlands,<sup>20</sup> and Italy.<sup>21</sup> There is probably an important potential for shortening LOS in European countries. Our data suggest that careful reorganisation of the process of care should accompany any attempt to reduce LOS to avoid detrimental effects on quality of care.<sup>22</sup> Two instruments which may help to achieve this are a critical pathway describing the procedures to be performed<sup>23 24</sup> and a tool to identify unnecessary delays generated in the process of care.23-25 The implementation of a critical pathway is one of the changes we plan to implement in our department. In this project, updated explicit quality of care criteria for patients with heart failure will be presented in the format of a criteria map, allowing physicians to verify the sequence, the timeliness, and the completeness of care provided to such patients. In addition, the criteria map will be used in retrospective chart reviews to monitor quality of care. Corrective measures will follow such observations.

One limitation of our study lies in its observational design. Without a controlled intervention, we can only speculate on the causality of associations between LOS and quality of care. Furthermore, because the data were abstracted from medical records, imperfect documentation may have diluted the observed associations. Since patients who died during hospitalisation were not included in the study—because one of its purposes was to assess the association between all three score of quality of care (admission, treatment and discharge) and LOS—we cannot rule out a different pattern of quality of care during the stay among these patients. Finally, the quality of care criteria that we used were rather simple and each considered only a segmented view of the care process; it is therefore possible that we may have missed some more subtle or holistic aspects of quality of care.

### Authors' affiliations

- M P Kossovsky, F P Sarasin, P Chopard, M Louis-Simonet,
- P Sigaud, T V Perneger, J-M Gaspoz, Group de Recherche et
- d'Analyse en Sytèmes et Soins Hospitaliers (GRASSH), Geneva University Hospitals
- P Chopard, T V Perneger, Quality of Care Unit, Geneva University Hospitals
- M P Kossovsky, F P Sarasin, P Chopard, M Louis-Simonet,

P Sigaud, J-M Gaspoz, Department of internal Medicine, Geneva University Hospitals, Switzerland

**T V Perneger**, Institute of Social and Preventive Medicine, University of Geneva

#### REFERENCES

- Polanczyk CA, Rohde LE, Dec GW, et al. Ten-year trends in hospital care for congestive heart failure: improved outcomes and increased use of resources. Arch Intern Med 2000;160:325–32.
- 2 Parmley WW. Cost-effective management of heart failure. Clin Cardiol 1996;19:240–2.

- 3 Levy E. From cost of illness to cost-effectiveness in heart failure. Eur Heart J 1998;19(Suppl P):P2-4.
- 4 Ryden-Bergsten T, Andersson F. The health care costs of heart failure in Sweden. J Intern Med 1999;246:275–84.
- 5 Cardiology Preeminence Roundtable. Beyond four walls. Cost-effective management of chronic congestive heart failure. Washington DC: The Advisory Board Company, 1994.
- Washington DC: The Advisory Board Company, 1994.
   Pine M, Norusis M, Jones B, et al. Predictions of hospital mortality rates: a comparison of data sources. Ann Intern Med 1997;126:347–54.
   Ashton CM, Kuykendall DH, Johnson ML, et al. A method of developing
- and weighting explicit process of care criteria for quality assessment. Med Care 1994;**32**:755–70.
- 8 Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
- Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Statist Assoc 1979;74:829–36.
- Cleary PD, Greenfield S, Mulley AG, et al. Variations in length of stay and outcomes for six medical and surgical conditions in Massachusetts and California. JAMA 1991;266:73–9.
   Philbin EF, Rogers VA, Sheesley KA, et al. The relationship between
- Philbin EF, Rogers VA, Sheesley KA, et al. The relationship between hospital length of stay and rate of death in heart failure. *Heart Lung* 1997;26:177–86.
- 12 Philbin EF, Roerden JB. Longer hospital length of stay is not related to better clinical outcomes in congestive heart failure. *Am J Manag Care* 1997;3:1285–91.
- 13 Chin MH, Goldman L. Correlates of early hospital readmission or death
- in patients with congestive heart failure. Am J Cardiol 1997; 79: 1640–4.
   Kossovsky MP, Sarasin FP, Perneger IV, et al. Unplanned readmissions of patients with congestive heart failure: do they reflect in-hospital quality
- of care or patient characteristics? Am J Med 2000;109:386–90.
   15 Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190–5.

- 16 Kuykendall DH, Ashton CM, Johnson ML, et al. Identifying complications and low provider adherence to normative practices using administrative data. *Health Serv Res* 1995;**30**:531–54.
- 17 Geraci JM, Ashton CM, Kuykendall DH, et al. In-hospital complications among survivors of admission for congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus. J Gen Intern Med 1995;10:307–14.
- 18 Geraci JM, Ashton CM, Kuykendall DH, et al. The association of quality of care and occurrence of in-hospital, treatment-related complications. Med Care 1999;37:140–8.
- 19 Stewart S, MacIntyre K, MacLeod MM, et al. Trends in hospitalization for heart failure in Scotland, 1990–1996. An epidemic that has reached its peak? Eur Heart J 2001;22:209–17.
- 20 Reitsma JB, Mosterd A, de Craen AJ, et al. Increase in hospital admission rates for heart failure in The Netherlands, 1980–1993. Heart 1996;76:388–92.
- 21 Albanese MC, Plewka M, Gregori D, et al. Use of medical resources and quality of life of patients with chronic heart failure: a prospective survey in a large Italian community hospital. Eur J Heart Fail 1999;1:411–7.
- Philbin EF, Rocco TA Jr, Lynch U, et al. Predictors and determinants of hospital length of stay in congestive heart failure in ten community hospitals. J Heart Lung Transplant 1997;16:548–55.
   Cardozo L, Ahrens S, Steinberg J, et al. Implementing a clinical pathway
- 23 Cardozo L, Ahrens Š, Steinberg J, et al. Implementing a clinical pathway for congestive heart failure: experiences at a teaching hospital. Qual Manag Health Care 1998;7:1–12.
- 24 Selker HP, Beshansky JR, Pauker SG, et al. The epidemiology of delays in a teaching hospital. The development and use of a tool that detects unnecessary hospital days. Med Care 1989;27:112–29.
- 25 Rosenstein AH. Using information management to implement a clinical resource management program. Jt Comm J Qual Improv 1997;23:653–66.

#### **Royal Society of Medicine**

#### Millennium Quality Improvement Travel Fellowship for 2002/3

#### Sponsored by the Forum on Quality in Health Care

The RSM Forum on Quality in Health Care organises and supports an annual Millennium Quality Improvement Travel Fellowship. It is intended to provide an opportunity for a person working on quality improvement in health care in the UK, who would not normally get such an opportunity through their work, to travel either nationally or internationally to study the theory and practice of quality improvement in health care. It is open to anyone working in health care in the UK, and there is no requirement to be a member of any particular profession or organisation.

The closing date for applications is 30 November 2002. There is no application form. Applicants are asked to provide a curriculum vitae which highlights their work on or contribution to quality improvement, and a statement of up to 600 words outlining how they would propose to use the travel fellowship to further both their own personal development and their work on and contribution to quality improvement in the UK. The successful applicant will be notified in January 2003.

Once an award has been made, the recipient is asked to prepare a budget and timetable outlining in more detail how he or she plans to use the award. The budget may seek funding of up to £1500. The timetable should usually show the award being used within a six month period.

Applications should be sent to Laura Milne, Academic Office, Royal Society of Medicine, 1 Wimpole Street, London W1G 0AG (telephone 020 7290 3942).